---
title: "IMVT-1402 in refractory rheumatoid arthritis achieved statistical significance in the Period 2… — 현대차증권 제약/바이오/의료기기 김현석 — DecisionGateway"
description: "statement by 현대차증권 제약/바이오/의료기기 김현석, recorded recently — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1d950-db09-704e-b002-22ff5c6d58f3"
meta:
  "og:description": "statement by 현대차증권 제약/바이오/의료기기 김현석, recorded recently — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "IMVT-1402 in refractory rheumatoid arthritis achieved statistical significance in the Period 2… — 현대차증권 제약/바이오/의료기기 김현석 — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

statement

# **IMVT-1402 in refractory rheumatoid arthritis achieved statistical significance in the Period 2 ACR20 response rate, with the 600mg group meeting key endpoints at week 28 on both ACR20 and ACR50 versus placebo.**

A statement by 현대차증권 제약/바이오/의료기기 김현석. Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *IMVT-1402의 난치성 류마티스관절염 Period 2 탑라인 결과 발표. IMVT-1402 600mg 투여군은 28주차 ACR20과 ACR50에서 모두 고용량군이 위약군 대비 통계적 유의성을 달성해 주요 평가지표 충족*

hmsecresearchPublished 2026-11-09 [ Read source](https://t.me/hmsecresearch/6167)

## **Discussion**

## **Related claims**

[**Immunovant's Phase 2b trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA) demonstrated excellent efficacy and safety, securing the validity of the development strategy.**report author · statement](https://dgw.tmarket.io/claims/01a1d4b6-f731-7ec4-848f-6e8b93480486) [**In the 600mg high-dose maintenance group, the ACR20 response rate was 92.5%, with nearly all patients maintaining response through week 28.**현대차증권 제약/바이오/의료기기 김현석 · statement](https://dgw.tmarket.io/claims/01a1d950-db21-760b-a0d0-62b887471209) [**The 600mg continuous dosing group recorded an ACR20 value of 92.5%, demonstrating excellent efficacy in absolute terms.**report author · statement](https://dgw.tmarket.io/claims/01a1d4b6-f6e3-7be5-ab83-bf2b785418ad) [**IMVT-1402 is designed so its binding epitope does not compete with albumin, allowing high-dose continuous administration without hypercholesterolemia concerns, whereas Batoclimab requires dose reduction after several weeks.**하나증권 제약/바이오 김선아 · statement](https://dgw.tmarket.io/claims/01a1d887-39ba-7ec3-9b03-4f53807d90d5) [**Following the D2T RA clinical success, the risk discount is reduced from 50% to 40%, leading to a revaluation of IMVT-1402.**report author · statement](https://dgw.tmarket.io/claims/01a1d4b6-f6fe-7e21-bace-a811a7b3596d) [**IMVT-1402 is the first clinical case to demonstrate that continuous high-dose dosing is possible without the hypercholesterolemia concerns seen with Batoclimab.**report author · statement](https://dgw.tmarket.io/claims/01a1d4b6-f6f1-7ada-9bde-36834d645c3f)

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts from 4,500+ Telegram channels — every claim cited. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1d950-db09-704e-b002-22ff5c6d58f3#webpage","@type":"WebPage","description":"statement by 현대차증권 제약/바이오/의료기기 김현석, recorded recently — verbatim quote and source citation.","name":"IMVT-1402 in refractory rheumatoid arthritis achieved statistical significance in the Period 2… — 현대차증권 제약/바이오/의료기기 김현석 — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1d950-db09-704e-b002-22ff5c6d58f3","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1d950-db09-704e-b002-22ff5c6d58f3#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1d950-db09-704e-b002-22ff5c6d58f3"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1d950-db09-704e-b002-22ff5c6d58f3#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"IMVT-1402 in refractory rheumatoid arthritis achieved…","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1d950-db09-704e-b002-22ff5c6d58f3#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-09","isBasedOn":"https://t.me/hmsecresearch/6167","text":"IMVT-1402의 난치성 류마티스관절염 Period 2 탑라인 결과 발표. IMVT-1402 600mg 투여군은 28주차 ACR20과 ACR50에서 모두 고용량군이 위약군 대비 통계적 유의성을 달성해 주요 평가지표 충족","url":"/claims/01a1d950-db09-704e-b002-22ff5c6d58f3"}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.